/
Other
Neoadjuvant Treatment
24
Pipeline Programs↗
24
Active Trials↗
19
Companies Involved↗
Neoadjuvant Treatment is an emerging landscape with 24 programs across 19 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd.. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 214
Phase 310
Approved
No programs
Analysis
Modality Breakdown
63%
Small molecule
15 of 24 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.
Analysis
Trial Status
66
clinical trials
Completed21 · 32%
Unknown status17 · 26%
Recruiting16 · 24%
Not yet recruiting8 · 12%
Terminated2 · 3%
Withdrawn2 · 3%
Clinical Trials
Trial Activity
66 trials
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
Recruiting·—·Phase 2·NCT05815303·92 enrolled
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
Recruiting·—·N/A·NCT05974007·1,500 enrolled
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Recruiting·—·Phase 3·NCT06102395·272 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)